RBC Capital Launches AbbVie (ABBV) Coverage, Expects Shares to Outperform Amid Competitive Fears

AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts.

On February 25, RBC Capital analyst Trung Huynh initiated coverage of AbbVie Inc. (NYSE:ABBV) with an Outperform rating and a $260 price target. The analyst noted that the shares have lagged due to concerns that AbbVie’s “beat-and-raise” story may be fading and that rising competition could slow its immunology growth.RBC does not share that view. The firm believes AbbVie is still early in expanding its treatments into new indications. Based on this outlook, the analyst expects the stock to continue outperforming.

A February 24 Reuters report said AbbVie plans to invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its North Chicago, Illinois campus. The goal is to increase US-based production of its neuroscience and obesity drugs. The company also wants to strengthen its domestic manufacturing presence.

This decision comes at a time when many pharmaceutical companies are shifting production to the US in response to steep tariffs on imported drugs. Construction is expected to begin in spring 2026, and both facilities are scheduled to start operating by 2029. The company plans to use advanced manufacturing technologies and artificial intelligence to support future drug production.

AbbVie also expects to hire about 300 employees at the site. This investment is part of its broader plan to spend $100 billion on US research and manufacturing over the next decade. The company is also evaluating additional domestic expansion opportunities.

AbbVie Inc. (NYSE:ABBV) is a global, diversified biopharmaceutical company focused on researching, developing, manufacturing, and selling medicines and therapies.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Most Promising Long-Term Stocks to Buy According to Hedge Funds and Goldman Sachs Dividend Stocks: Top 14 Stock Picks

Disclosure: None.  Follow Insider Monkey on Google News.